Acute Myelogenous Leukemia: Clinical Trials

14 trials for Acute Myelogenous Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 14 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 9, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 22Completed 1, Not yet recruiting 1

Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia
Phase 2 / Phase 3Not yet recruitingActinium Pharmaceuticals3062026-01-012025-09-10
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Iomab-B, Conventional Care, HCT - Acute Myeloid Leukemia, Leukemia, Acute Myeloid
Phase 3Active not recruitingActinium Pharmaceuticals1532016-06-012023-07-19
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI) - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Phase 3CompletedNorthwell Health102014-12-012022-04-07
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units. - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Phase 3CompletedMesoblast, Ltd.492013-08-012020-06-26
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia
Phase 3TerminatedHospital Israelita Albert Einstein32012-12-012017-03-03
Double Cord Versus Haploidentical (BMT CTN 1101)
Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant - Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Phase 3CompletedMedical College of Wisconsin3682012-06-012021-12-01
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) - Myeloid Malignancies, Acute Myelogenous Leukemia
Phase 3TerminatedHackensack Meridian Health532010-06-162026-04-03
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Cytarabine plus Daunorubicin [Arm II (AD regimen)] - Acute Myelogenous Leukemia
Phase 3UnknownCooperative Study Group A for Hematology3162010-05-012010-06-17
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Procrit - Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 3CompletedM.D. Anderson Cancer Center512008-03-012018-05-30
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Single Umbilical Cord Blood Unit Transplant, Double Umbilical Cord Blood Unit Transplant, Total Body Irradiation - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Phase 3CompletedMedical College of Wisconsin2242006-12-012021-10-28
A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)
cytosine arabinoside - Acute Myelogenous Leukemia
Phase 3CompletedNorthern Italy Leukemia Group5732006-11-012016-03-31
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
clofarabine (IV formulation), placebo, cytarabine - Acute Myelogenous Leukemia
Phase 3CompletedGenzyme, a Sanofi Company3262006-08-012014-04-14
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
Decitabine - Acute Myelogenous Leukemia
Phase 2 / Phase 3CompletedM.D. Anderson Cancer Center502006-08-012013-03-04
High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
arm II - ACUTE MYELOGENOUS LEUKEMIA
Phase 3CompletedCooperative Study Group A for Hematology3982001-08-012011-06-10

Narrower conditions

Leukemia, Myeloid, Acute (14)  ·  Myelodysplastic Syndromes (5)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Leukemia (4)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4)  ·  Hodgkin Disease (3)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Myeloproliferative Disorders (2)  ·  Burkitt Lymphoma (1)  ·  Graft vs Host Disease (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)

Broader conditions

Hematologic Diseases (14)  ·  Hemic and Lymphatic Diseases (14)  ·  Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Leukemia, Myeloid (13)  ·  Leukemia (10)  ·  Bone Marrow Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Leukemia, Lymphoid (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Chronic Disease (4)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)

Interventions

Cyclophosphamide (4)  ·  Whole-Body Irradiation (4)  ·  Cytarabine (3)  ·  fludarabine (3)  ·  Daunorubicin (2)  ·  fludarabine phosphate (2)  ·  Busulfan (1)  ·  Calcineurin Inhibitors (1)  ·  Clofarabine (1)  ·  Cyclosporine (1)  ·  Decitabine (1)  ·  Dosage Forms (1)  ·  Epoetin Alfa (1)  ·  Idarubicin (1)  ·  Methotrexate (1)

Sponsors

Actinium Pharmaceuticals (2)  ·  Cooperative Study Group A for Hematology (2)  ·  M.D. Anderson Cancer Center (2)  ·  Medical College of Wisconsin (2)  ·  Genzyme, a Sanofi Company (1)  ·  Hackensack Meridian Health (1)  ·  Hospital Israelita Albert Einstein (1)  ·  Mesoblast, Ltd. (1)  ·  Northern Italy Leukemia Group (1)  ·  Northwell Health (1)

Countries

United States (9)  ·  Canada (3)  ·  Italy (2)  ·  South Korea (2)  ·  Australia (1)  ·  Brazil (1)  ·  France (1)  ·  Germany (1)

Top investigators

Mary Horowitz, MD, MS (2)  ·  Avinash Desai, MD (1)  ·  Donna Skerrett, MD, MS (1)  ·  Elizabeth J. Shpall, MD (1)  ·  Farhad Ravandi-Kashani, MD (1)  ·  Je Hwan Lee, Professor (1)  ·  Je Hwan Lee, professor (1)  ·  Joel A Brochstein, MD (1)  ·  Jorge E. Cortes, M.D. (1)  ·  Michele Donato, MD (1)  ·  Paulo V Campregher, MD (1)  ·  Renato Bassan, MD (1)

Results publications

PMID 21828126, PMID 22585697, PMID 25354103, PMID 30948365, PMID 31978214, PMID 32855275, PMID 33475736, PMID 34273598, PMID 35350938, PMID 37088401, PMID 37120135, PMID 39298738, PMID 39846144, PMID 40227676, PMID 41350757

NIH funding

U24CA076518 (2), 2008 (1), U01HL069294 (1), U10HL069294 (1)